Tolvaptan treatment increases serum sodium via aquaresis—ie,
increased electrolyte-free water excretion—and thus presents an advantage in patients with syndrome of
inappropriate secretion of antidiuretic hormone or other euvolemic states or hypervolemic
hyponatremia.